Skip to content
Biotechnology, Medical Health Aged Care

Elon Musk’s Neuralink: Dr Steve Kassem available to comment

Neuroscience Research Australia < 1 mins read

Dr Steve Kassem from Neuroscience Research Australia is available to provide his expert comment on Elon Musk's Neuralink. 

Dr Kassem is a brain cartographer and works at NeuRA's Brain Mapping Facility with Professor George Paxinos AO. He is an experienced media spokesperson, having appeared on radio and television numerous times, as well as being a regular at Sydney Science Festival. 


Contact details:

Contact Nadia

Senior Communications & PR Officer

0452 140 477

n.razzhigaeva@neura.edu.au

Media

More from this category

  • Medical Health Aged Care
  • 23/01/2025
  • 00:26
Novotech

Novotech Releases Comprehensive Report on Oncolytic Virus Therapy

Explore the latest insights into global clinical trial trends, innovations, and strategies shaping the future of oncolytic virus therapy. SYDNEY–BUSINESS WIRE– Novotech, the global…

  • Contains:
  • Federal Election, Medical Health Aged Care
  • 22/01/2025
  • 09:52
Public Health Association of Australia

Media alert – Next Aust Govt must act on obesity, gambling, and climate harms

Next Aust Govt must act on obesity, gambling, and climate harms The Public Health Association of Australia (PHAA), which represents 2,000 public health professionals, will today release its seven election priorities ahead of this year’s federal election. Media are invited to Mural Hall, Parliament House, to hear PHAA CEO, Adjunct Professor Terry Slevin, discuss the importance of strengthening our nation’s public health programs. The Association’s election priorities, available at voteforpublichealth.com are: Establish a permanent Australian Centre for Disease Control Invest in prevention to save lives and money Act on obesity to help more Australians maintain a healthy weight Invest in…

  • Contains:
  • Biotechnology, Business Company News
  • 22/01/2025
  • 09:41
Jane Morgan Management

LTR Pharma Limited (ASX:LTP) Signs National Pharmacy Distribution Agreement with Symbion, Establishing Nationwide Distribution Network for SPONTAN®

22 January 2025 – Sydney, Australia | ASX-listed LTR Pharma Limited (ASX:LTP) has announced a strategic partnership with Symbion Pty Ltd, which is one of the largest pharmaceutical wholesalers in Australia. This will facilitate the nationwide distribution of novel nasal spray treatment for Erectile Dysfunction (ED), SPONTAN®. The non-exclusive agreement, which commences on 1 March 2025, enables LTR Pharma to leverage Symbion's extensive network of over 3,900 pharmacies across the country. This collaboration will play a vital role in supporting the early access scheme that LTR will use and sets a new foundation for SPONTAN’s commercial launch following the appropriate…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.